Pretreatment characteristics in the primary cohort of 210 CN-AML patients according to LEF1 expression levels
| Variable . | LEF1high, n = 105 . | LEF1low, n = 105 . | P . |
|---|---|---|---|
| Median age, y (range) | 57 (17-77) | 59 (18-83) | .56 |
| Female sex, no. (%) | 59 (56) | 63 (60) | .67 |
| Secondary or treatment-related AML, no. (%) | 4 (4) | 6 (6) | .75 |
| FAB subtype, no. | .21 | ||
| M0 | 5 | 1 | |
| M1 | 22 | 35 | |
| M2 | 32 | 33 | |
| M4 | 27 | 19 | |
| M5 | 12 | 13 | |
| M6 | 6 | 3 | |
| RAEB-2 | 1 | 1 | |
| Median WBC, 109/L (range) | 21.0 (0.9-216) | 44.6 (0.85-486) | < .001 |
| Median BM blasts, % (range) | 80 (11-100) | 87.5 (17-100) | .02 |
| Median platelet count, 109/L (range) | 64 (6-280) | 48 (9-471) | .04 |
| FLT3-ITD present, no. (%) | 25 (24) | 61 (58) | < .001 |
| NPM1 mutated, no. (%) | 52 (50) | 61 (58) | .27 |
| CEBPA mutated, no. (%) | 11 (11) | 12 (12) | > .99 |
| Monaoallelic CEBPA mutation | 3 | 8 | |
| Biallelic CEBPA mutation | 8 | 4 | |
| Missing data | 6 | 3 | |
| ELN genetic group,25 no. (%) | .01 | ||
| Favorable | 49 (48) | 31 (30) | |
| Intermediate-I | 53 (52) | 71 (70) | |
| Missing data | 3 | 3 | |
| IDH1 mutated, no. (%) | 8 (12) | 10 (12) | > .99 |
| Missing data | 40 | 21 | |
| IDH2 mutated, no. (%) | 11 (17) | 15 (18) | > .99 |
| Codon R140 mutation | 11 | 15 | |
| Codon R172 mutation | 0 | 0 | |
| Missing data | 40 | 21 | |
| FLT3-TKD (D835) mutated, no. (%) | 9 (9) | 8 (8) | .81 |
| Missing data | 1 | 0 | |
| MLL-PTD present, no. (%) | 15 (15) | 11 (11) | .41 |
| Missing data | 4 | 2 | |
| High ERG expression,* no. (%) | 19 (18) | 34 (32) | .03 |
| High BAALC expression,* no. (%) | 52 (50) | 53 (50) | 1.0 |
| High MN1 expression,* no. (%) | 53 (50) | 52 (50) | 1.0 |
| Variable . | LEF1high, n = 105 . | LEF1low, n = 105 . | P . |
|---|---|---|---|
| Median age, y (range) | 57 (17-77) | 59 (18-83) | .56 |
| Female sex, no. (%) | 59 (56) | 63 (60) | .67 |
| Secondary or treatment-related AML, no. (%) | 4 (4) | 6 (6) | .75 |
| FAB subtype, no. | .21 | ||
| M0 | 5 | 1 | |
| M1 | 22 | 35 | |
| M2 | 32 | 33 | |
| M4 | 27 | 19 | |
| M5 | 12 | 13 | |
| M6 | 6 | 3 | |
| RAEB-2 | 1 | 1 | |
| Median WBC, 109/L (range) | 21.0 (0.9-216) | 44.6 (0.85-486) | < .001 |
| Median BM blasts, % (range) | 80 (11-100) | 87.5 (17-100) | .02 |
| Median platelet count, 109/L (range) | 64 (6-280) | 48 (9-471) | .04 |
| FLT3-ITD present, no. (%) | 25 (24) | 61 (58) | < .001 |
| NPM1 mutated, no. (%) | 52 (50) | 61 (58) | .27 |
| CEBPA mutated, no. (%) | 11 (11) | 12 (12) | > .99 |
| Monaoallelic CEBPA mutation | 3 | 8 | |
| Biallelic CEBPA mutation | 8 | 4 | |
| Missing data | 6 | 3 | |
| ELN genetic group,25 no. (%) | .01 | ||
| Favorable | 49 (48) | 31 (30) | |
| Intermediate-I | 53 (52) | 71 (70) | |
| Missing data | 3 | 3 | |
| IDH1 mutated, no. (%) | 8 (12) | 10 (12) | > .99 |
| Missing data | 40 | 21 | |
| IDH2 mutated, no. (%) | 11 (17) | 15 (18) | > .99 |
| Codon R140 mutation | 11 | 15 | |
| Codon R172 mutation | 0 | 0 | |
| Missing data | 40 | 21 | |
| FLT3-TKD (D835) mutated, no. (%) | 9 (9) | 8 (8) | .81 |
| Missing data | 1 | 0 | |
| MLL-PTD present, no. (%) | 15 (15) | 11 (11) | .41 |
| Missing data | 4 | 2 | |
| High ERG expression,* no. (%) | 19 (18) | 34 (32) | .03 |
| High BAALC expression,* no. (%) | 52 (50) | 53 (50) | 1.0 |
| High MN1 expression,* no. (%) | 53 (50) | 52 (50) | 1.0 |
CN-AML indicates cytogenetically normal acute myeloid leukemia; FAB, French-American-British classification; WBC, white blood cell count; ITD, internal tandem duplication; ELN, European Leukemia Net; TKD, tyrosine kinase domain; and PTD, partial tandem duplication.
High BAALC and MN1 expression were defined as an expression level above the median of all samples, respectively, and high ERG expression was defined as an expression level above the 75th percentile.19,26